insulin
Insulin shortage puts millions at risk, study shows
In the next 12 years, half of those with type 2 diabetes won’t be able to receive potentially life-saving insulin unless access to the drug improves, new research shows. Read more
Novo Nordisk to acquire all shares of Bristol University spin-out company
Novo Nordisk, global healthcare company, has acquired all of the shares of a University of Bristol spin-out company — Ziylo — giving it full rights to a glucose blinding molecule platform to develop glucose responsive insulins. Read more
A small dose — the latest research and industry developments, July-August 2018
A brief round up of some of the latest developments in the industry, including a review into medical marijuana and a potential win for Trump in drug pricing… Read more
A small dose — a capsule view of some key developments in the industry, June 2018
A brief round-up of some of the developments in the industry including a step in the right direction for oral insulin and an overview of Alantra Pharma’s Fast 50 index… Read more
Device inspired by spider’s web may be a game-changer for diabetes
A device that takes inspiration from a spider’s web that may be a game-changer in the control of Type 1 diabetes has been developed by researchers from Cornell University. Read more
The top five tweets: From Brexit to Huntington’s disease — what did EPM readers enjoy this week?
Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more
Phillips-Medisize & Dance Biopharm working on connected insulin inhaler
Phillips-Medisize has entered into an agreement with biotechnology company Dance Biopharm to develop a connected insulin inhaler. Read more
Fast-acting mealtime insulin approved by FDA
Global healthcare company, Novo Nordisk, has revealed that the US Food and Drug Administration (FDA) has approved its fast-acting mealtime insulin, Fiasp, for the improvement of glycaemic control in adults with diabetes. Read more
Immunotherapy for type I diabetes safe and well-tolerated, report study authors
A potential new therapy for type I diabetes patients has been found to be safe and does not accelerate decline in β cell function — important in the production of insulin — in a recently published clinical trial. Read more
Amrita Banerjee discusses oral insulin delivery
Amrita Banerjee, post-doctoral scholar, University of California Santa Barbara talks oral insulin and needle-free delivery of protein Read more
Novo Nordisk submits new drug application for faster-acting insulin aspart
Novo Nordisk has submitted a New Drug Application (NDA) for a faster-acting insulin aspart to the US Food and Drug Administration (FDA) Read more
5 drug developments we like
EPM selects five noteworthy drugs and drug delivery developments from the past month Read more
Intestinal patch allows oral insulin dosage
Researchers have developed an intestinal patch device containing insulin that can be swallowed in a capsule Read more
Smart insulin pen wins Red Dot Design Award
Cambridge Consultants has won a Red Dot Design Award for its KiCoPen smart insulin pen concept Read more
Iran's insulin production and how it affects pharma
Y. Shashidhar, partner & managing director, South Asia, Middle East & North Africa, Frost & Sullivan talks about how the local production of insulin from Novo Nordisk’s new plant in Iran could impact the pharma market Read more
Japan approves Sanofi's new insulin injection for diabetes mellitus
The Ministry of Health, Labor and Welfare in Japan has granted marketing authorisation for Sanofi's insulin glargine [rDNA origin] injection, 300 u/ml, a next-generation basal insulin for the treatment of type 1 and type 2 diabetes mellitus. Read more
Two-in-one device breaks cycle of poor diabetes management
Final-year Brunel University design student Oscar Daws has come up with a streamlined device that aims to vastly improve patients’ self-management of diabetes and has been selected for a prestigious exhibition on London’s South Bank. Read more
Copyright: MannKind Corporation
Sanofi and MannKind announce global licensing agreement for Afrezza
The new rapid-acting inhaled insulin therapy is for treating adults with type 1 and type 2 diabetes. Read more
FDA accepts Sanofi's NDA for basal insulin Toujeo
The acceptance of the NDA follows the acceptance of the marketing authorization dossier for Toujeo by the European Medicines Agency (EMA) for EU countries on 27 May 2014. Read more
